During the last session, Pacific Biosciences of California Inc (NASDAQ:PACB)’s traded shares were 20.79 million, with the beta value of the company hitting 1.86. At the end of the trading day, the stock’s price was $1.48, reflecting an intraday gain of 8.82% or $0.12. The 52-week high for the PACB share is $6.83, that puts it down -361.49 from that peak though still a striking 21.62% gain since the share price plummeted to a 52-week low of $1.16. The company’s market capitalization is $405.31M, and the average trade volume was 10.04 million shares over the past three months.
Pacific Biosciences of California Inc (PACB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.19. PACB has a Sell rating from 1 analyst(s) out of 11 analysts who have looked at this stock. 4 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.16.
Pacific Biosciences of California Inc (NASDAQ:PACB) trade information
Pacific Biosciences of California Inc (PACB) registered a 8.82% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 8.82% in intraday trading to $1.48, hitting a weekly high. The stock’s 5-day price performance is -7.50%, and it has moved by -20.00% in 30 days. Based on these gigs, the overall price performance for the year is -77.94%.
The consensus price target of analysts on Wall Street is $3, which implies an increase of 50.67% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $4 respectively. As a result, PACB is trading at a discount of -170.27% off the target high and -35.14% off the low.
Pacific Biosciences of California Inc (PACB) estimates and forecasts
In the rating firms’ projections, revenue will increase 21.01% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 41.26M as predicted by 11 analyst(s). Meanwhile, a consensus of 11 analyst(s) estimates revenue growth to 43.99M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 38.81M and 36.01M respectively. In this case, analysts expect current quarter sales to grow by 6.31% and then jump by 22.15% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -9.76%. While earnings are projected to return 56.58% in 2025, the next five years will return 34.08% per annum.
PACB Dividends
Pacific Biosciences of California Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 26.0 million shares, is of VANGUARD GROUP INC’s that is approximately 9.6443% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $35.62 million.
